Avalo Therapeutics entered into a milestone buyout option and amendment agreement with former AlmataBio securityholders on April 26, 2026. The deal requires Avalo to pay $2.25 million and grants the securityholders an option exercisable within 90 days to receive an additional $5.125 million in cash, shares, or a combination of both. Exercising the option would replace a previously disclosed $15 million contingent milestone payment that was due when the first patient was dosed in a Phase 3 trial of the company’s lead asset, abdakibart (AVTX‑009).
Continue reading for full analysis...